# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Joseph Catanzaro downgrades Aadi Bioscience (NASDAQ:AADI) from Overweight to Neutral and lowers the pr...
Aadi Bioscience halts its PRECISION1 trial of nab-sirolimus in solid tumors with TSC1/TSC2 mutations due to insufficient effica...
HC Wainwright & Co. analyst Robert Burns reiterates Aadi Bioscience (NASDAQ:AADI) with a Neutral.
TD Cowen analyst Boris Peaker downgrades Aadi Bioscience (NASDAQ:AADI) from Buy to Hold.
An analysis by the Independent Data Monitoring Committee demonstrated that the study was unlikely to exceed an efficacy thresho...
Aadi Bioscience (NASDAQ:AADI) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.6...